What Counts as a Psychedelic?
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper |
|---|---|
| Key points | Argues that the lack of a consensus definition for "psychedelic" allows regulatory and commercial decisions to rest on unexamined normative boundaries. Contends that exclusions of structurally similar substances like PCP, methamphetamine, and diphenhydramine reflect reputational concerns rather than pharmacological distinctions, risking drug elitism with classist and racist antecedents. Calls for pre-established, publicly articulated criteria for the label. |
Abstract
The term “psychedelic” lacks a consensus definition, yet a growing body of regulatory and commercial infrastructure—FDA clinical-trial guidance, AMA reimbursement codes, research grants, and insurance coverage decisions—turns on whether a given substance falls within the category. This short essay argues that the boundaries of the “psychedelic” label are doing significant normative work that is too often left unexamined. While LSD, psilocybin, mescaline, MDMA, and ketamine are commonly included, structurally similar substances such as PCP, methamphetamine, and diphenhydramine are routinely excluded—not because of meaningful pharmacological distinctions, but because their reputations would tarnish the “psychedelic” brand. The essay traces the etymology of the term, examines its “classical” pharmacological criteria, and shows how the current categorization risks perpetuating forms of drug elitism with classist and racist antecedents (recalling the crack-versus-cocaine sentencing disparity). It calls on academics, regulators, and industry actors to pre-establish and publicly articulate the criteria by which a substance qualifies as “psychedelic,” so that those criteria can be subjected to critique and refinement.